Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Prologis raises core FFO guidance midpoint after Q2 results beat (SeekingAlpha) +++ PROLOGIS Aktie +4,49%

BIOMARIN Aktie

 >BIOMARIN Aktienkurs 
48.29 EUR    -1.1%    (Tradegate)
Ask: 49.89 EUR / 400 Stück
Bid: 49.63 EUR / 410 Stück
Tagesumsatz: 1 Stück
Realtime Kurs von 8 bis 22 Uhr!
BIOMARIN Aktie über LYNX handeln
>BIOMARIN Performance
1 Woche: -1,3%
1 Monat: +0,7%
3 Monate: -8,5%
6 Monate: -19,7%
1 Jahr: -36,7%
laufendes Jahr: -22,7%
>BIOMARIN Aktie
Name:  BIOMARIN PHAR. DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US09061G1013 / 924801
Symbol/ Ticker:  BM8 (Frankfurt) / BMRN (NASDAQ)
Kürzel:  FRA:BM8, ETR:BM8, BM8:GR, NASDAQ:BMRN
Index:  -
Webseite:  https://www.biomarin.com/
Marktkapitalisierung:  9580 Mio. EUR
Umsatz:  2548.11 Mio. EUR
EBITDA:  696.73 Mio. EUR
Gewinn je Aktie:  2.038 EUR
Schulden:  519.95 Mio. EUR
Liquide Mittel:  1096.98 Mio. EUR
Umsatz-/ Gewinnwachstum:  14.8% / 109.4%
KGV/ KGV lG:  21.36 / 13.64
KUV/ KBV/ PEG:  3.83 / 1.91 / 0.83
Gewinnm./ Eigenkapitalr.:  17.76% / 9.64%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  BIOMARIN
Letzte Datenerhebung:  16.07.25
>BIOMARIN Eigentümer
Aktien: 191.78 Mio. St.
f.h. Aktien: 179.36 Mio. St.
Insider Eigner: 0.85%
Instit. Eigner: 99.01%
>BIOMARIN Peer Group

 
10.07.25 - 19:45
 Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
 
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report....
08.07.25 - 17:30
 Here′s Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock (Zacks)
 
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service....
01.07.25 - 14:45
 BioMarin Announces Completion of Acquisition of Inozyme (PR Newswire)
 
SAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (Nasdaq: INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The......
25.06.25 - 17:30
 Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term (Zacks)
 
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service....
24.06.25 - 17:12
 BioMarin Presents Long-term Efficacy And Safety Of Roctavian (AFX)
 
WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) Tuesday announced new data underscoring the long-term efficacy and safety of Roctavian (valoctocogene roxaparvovec-rvox).The Phase 3 GENE......
20.06.25 - 23:03
 Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders (GlobeNewswire EN)
 
BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), which was scheduled to be held on June 25, 2025, in light of the previously announced acquisition (the “Acquisition”) by BioMarin Pharmaceutical Inc. (“BioMarin”)....
28.05.25 - 19:00
 Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock? (Zacks)
 
Investors need to pay close attention to BioMarin Pharmaceutical stock based on the movements in the options market lately....
21.05.25 - 01:01
 Insiderhandel: GVP, Chief Accounting Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 105928 USD (Insiderkauf)
 
Burkhart, Erin - Vorstand - Tag der Transaktion: 2025-05-20...
19.05.25 - 16:45
 BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz (Zacks)
 
BMRN's acquisition of INZY is set to add a late-stage enzyme replacement therapy for a rare genetic condition. The deal is likely to be closed by September....
16.05.25 - 14:18
 BioMarin To Acquire Inozyme Pharma For About $270 Mln In Cash (AFX)
 
WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) and Inozyme Pharma, Inc. (INZY) Friday said that BioMarin has agreed to acquire Inozyme for about $270 million or $4 per share, in cash.T......
16.05.25 - 14:06
 BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
16.05.25 - 13:33
 BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma (PR Newswire)
 
Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to......
12.05.25 - 16:18
 BioMarin Reports New Positive CANOPY Studies Data For Voxzogo (AFX)
 
WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) Monday announced new data from studies of Voxzogo in children with achondroplasia and other skeletal conditions.Voxzogo is already approv......
12.05.25 - 15:06
 BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings (PR Newswire)
 
New data in children under 5 years with achondroplasia showed treatment with VOXZOGO was associated with improvement in tibial bowing, a common cause of pain and impaired function Data from the largest retrospective, multi-year observational study of more than 600 children and adults with......
07.05.25 - 01:01
 Insiderhandel: EVP, Chief Commercial Officer verkauft Aktien von Biomarin Pharmaceutical im Wert von 17723 USD (Insiderkauf)
 
Hubbard, Cristin - Vorstand - Tag der Transaktion: 2025-05-02...
02.05.25 - 21:15
 BioMarin′s First-Quarter Earnings & Sales Beat Estimates (Zacks)
 
BMRN reports encouraging first-quarter results. The company reiterates its financial guidance for 2025....
02.05.25 - 03:30
 BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
 
While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values....
02.05.25 - 01:30
 BioMarin outlines 2025 revenue growth with VOXZOGO expected to reach $950M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
01.05.25 - 22:36
 Biomarin Pharmaceutical Inc. Q1 Profit Increases, Beats Estimates (AFX)
 
WASHINGTON (dpa-AFX) - Biomarin Pharmaceutical Inc. (BMRN) released earnings for its first quarter that increased from last year and beat the Street estimates.The company's bottom line came in at ......
01.05.25 - 22:09
 BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance (PR Newswire)
 
First Quarter 2025 Total Revenues of $745 million (+15% Y/Y and +17% at Constant Currency Y/Y) First Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $0.95 (+107% Y/Y) First Quarter 2025 Non-GAAP Diluted EPS of $1.13 (+59% Y/Y) Conference Call and Webcast Scheduled Today at 4:30 p.m.......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Vollkommene Politik besteht darin, niemals das letzte Motiv zu enthüllen. - Benjamin Disraeli
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!